Importantly, a report by Costa and colleagues examined the concentration of crizotinib in the CSF of an ALK+ NSCLC pt who had progressed on crizotinib for BM and was treated with whole brain irradiation (WBI) and then resumed crizotinib after WBI [43]. This evidence concerns the gene ALK and non-small cell lung carcinoma.